Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study.
Levitz D, Chao Foong Y, Sanfilippo P, Spelman T, Rath L, Roldan A, Lal A, Monif M, Jokubaitis V, Ozakbas S, Alroughani R, Boz C, Terzi M, Kalincik T, Blanco Y, Foschi M, Surcinelli A, Buzzard K, Skibina O, Laureys G, Van Hijfte L, Ramo-Tello C, Soysal A, Sanchez-Menoyo JL, Habek M, Cartechini E, Rojas JI, Karabudak R, Willekens B, Al-Harbi T, Fragoso Y, Castillo-Triviño T, Decoo D, Aragon de Vecino MC, Skromne E, Sirbu CA, Zhu C, Merlo D, Gresle M, Butzkueven H, Van Der Walt A. Levitz D, et al. Among authors: laureys g. Ther Adv Neurol Disord. 2024 Nov 7;17:17562864241278496. doi: 10.1177/17562864241278496. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39525878 Free PMC article.
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
Zhou Y, Claflin SB, Stankovich J, van der Mei I, Simpson S Jr, Roxburgh RH, Kalincik T, Blizzard L, Lugaresi A, Alroughani R, Sajedi SA, Butzkueven H, Pucci E, Spitaleri D, Granella F, Cristiano E, Yamout B, Hughes S, Gouider R, Sánchez Menoyo JL, Olascoaga J, McGuigan C, Shaw C, Kermode AG, Kasa K, Al-Harbi T, Altintas A, Laureys G, Fragoso Y, Hardy TA, Csepany T, Sirbu CA, Decoo D, Sas A, Alvarez-Cermeño JC, Kotkata K, Millán-Pascual J, Taylor BV. Zhou Y, et al. Among authors: laureys g. Mult Scler. 2020 Nov;26(13):1765-1774. doi: 10.1177/1352458519881994. Epub 2019 Oct 31. Mult Scler. 2020. PMID: 31668127
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
Kunchok A, Malpas C, Nytrova P, Havrdova EK, Alroughani R, Terzi M, Yamout B, Hor JY, Karabudak R, Boz C, Ozakbas S, Olascoaga J, Simo M, Granella F, Patti F, McCombe P, Csepany T, Singhal B, Bergamaschi R, Fragoso Y, Al-Harbi T, Turkoglu R, Lechner-Scott J, Laureys G, Oreja-Guevara C, Pucci E, Sola P, Ferraro D, Altintas A, Soysal A, Vucic S, Grand'Maison F, Izquierdo G, Eichau S, Lugaresi A, Onofrj M, Trojano M, Marriott M, Butzkueven H, Kister I, Kalincik T. Kunchok A, et al. Among authors: laureys g. Mult Scler Relat Disord. 2020 Feb;38:101868. doi: 10.1016/j.msard.2019.101868. Epub 2019 Nov 25. Mult Scler Relat Disord. 2020. PMID: 31877445
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; Tysabri Observational Program (TOP) Investigators. Butzkueven H, et al. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668. doi: 10.1136/jnnp-2019-322326. Epub 2020 Mar 31. J Neurol Neurosurg Psychiatry. 2020. PMID: 32234967 Free PMC article.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Trojano M, Patti F, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Prat A, Girard M, Grammond P, Sola P, Ferraro D, Ozakbas S, Bergamaschi R, Sá MJ, Cartechini E, Boz C, Granella F, Hupperts R, Terzi M, Lechner-Scott J, Spitaleri D, Van Pesch V, Soysal A, Olascoaga J, Prevost J, Aguera-Morales E, Slee M, Csepany T, Turkoglu R, Sidhom Y, Gouider R, Van Wijmeersch B, McCombe P, Macdonell R, Coles A, Malpas CB, Butzkueven H, Vukusic S, Kalincik T; MSBase; OFSEP investigators. Roos I, et al. Brain. 2020 Sep 1;143(9):2742-2756. doi: 10.1093/brain/awaa231. Brain. 2020. PMID: 32947619 Free article.
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Zhong M, van der Walt A, Stankovich J, Kalincik T, Buzzard K, Skibina O, Boz C, Hodgkinson S, Slee M, Lechner-Scott J, Macdonell R, Prevost J, Kuhle J, Laureys G, Van Hijfte L, Alroughani R, Kermode AG, Butler E, Barnett M, Eichau S, van Pesch V, Grammond P, McCombe P, Karabudak R, Duquette P, Girard M, Taylor B, Yeh W, Monif M, Gresle M, Butzkueven H, Jokubaitis VG. Zhong M, et al. Among authors: laureys g. Mult Scler. 2022 May;28(6):958-969. doi: 10.1177/13524585211049986. Epub 2021 Oct 8. Mult Scler. 2022. PMID: 34623947
247 results